A5063794256- CAR-T cell therapy research
- Biosimilars and Bioanalytical Methods
- Biomedical Ethics and Regulation
- Viral Infectious Diseases and Gene Expression in Insects
- Health, Medicine and Society
- Virus-based gene therapy research
- Immune cells in cancer
- Chemokine receptors and signaling
- Nanoplatforms for cancer theranostics
- Psychoanalysis and Psychopathology Research
- Migration, Identity, and Health
- Nanowire Synthesis and Applications
Novartis (Switzerland)
2021-2023
Novartis Institutes for BioMedical Research
2023
Université de Lorraine
2015
Abstract CAR T-cell product quality and stemness (Tstem) are major determinants of in vivo expansion, efficacy, clinical response. Prolonged ex culturing is known to deplete Tstem, affecting outcome. YTB323, a novel autologous CD19-directed therapy expressing the same validated as tisagenlecleucel, manufactured using next-generation platform <2 days. Here, we report preclinical development preliminary data YTB323 adults with relapsed/refractory diffuse large B-cell lymphoma (r/r...
<p>Supplementary Fig. S1. Preclinical evaluation and characterization of YTB323 CTL*019 for Donor 2 3; Supplementary S2. Differential gene expression cells versus (preclinical); S3. validation YTB323; S4. Dose-dependent expansion (Cmax AUC0-21d) in NSG mice with NALM6; S5. CD4:CD8 ratio comparison leukapheresis cell products tisagenlecleucel; S6. Stemness memory differentiation signatures are retained or enriched final product; S7. tisagenlecleucel S8. Naive/TSCM a naive stem-like...
<p>Supplementary Fig. S1. Preclinical evaluation and characterization of YTB323 CTL*019 for Donor 2 3; Supplementary S2. Differential gene expression cells versus (preclinical); S3. validation YTB323; S4. Dose-dependent expansion (Cmax AUC0-21d) in NSG mice with NALM6; S5. CD4:CD8 ratio comparison leukapheresis cell products tisagenlecleucel; S6. Stemness memory differentiation signatures are retained or enriched final product; S7. tisagenlecleucel S8. Naive/TSCM a naive stem-like...
<p>Supplementary Table S1. Bridging chemotherapies by ATC class and preferred term (safety set); Supplementary S2. Lymphodepleting S3. Cytokine release syndrome following YTB323 infusion; S4. Neurological adverse reactions S5. Summary of cellular kinetic parameters in peripheral blood flow cytometry for at DL1 DL2; S6. qPCR DL2.</p>
<p>Supplementary Table S1. Bridging chemotherapies by ATC class and preferred term (safety set); Supplementary S2. Lymphodepleting S3. Cytokine release syndrome following YTB323 infusion; S4. Neurological adverse reactions S5. Summary of cellular kinetic parameters in peripheral blood flow cytometry for at DL1 DL2; S6. qPCR DL2.</p>
<p>Supplementary Table S1. Bridging chemotherapies by ATC class and preferred term (safety set); Supplementary S2. Lymphodepleting S3. Cytokine release syndrome following YTB323 infusion; S4. Neurological adverse reactions S5. Summary of cellular kinetic parameters in peripheral blood flow cytometry for at DL1 DL2; S6. qPCR DL2.</p>
Abstract Background: The CSF-1/CSF-1R (colony-stimulating factor-1) pathway plays a significant role in the tumor microenvironment via regulation of tumor-associated macrophages (TAMs). Lacnotuzumab (MCS110) is humanized monoclonal antibody against CSF-1. may counteract suppressive induced by CSF-1, potentially enhancing efficacy PD-1 inhibition. Methods: MCS110Z2102 phase 1b/2 study cancer patients with advanced malignancies treated lacnotuzumab combined inhibitor spartalizumab. Eligible...
<div>Abstract<p>CAR T-cell product quality and stemness (Tstem) are major determinants of in vivo expansion, efficacy, clinical response. Prolonged ex culturing is known to deplete Tstem, affecting outcome. YTB323, a novel autologous CD19-directed CAR therapy expressing the same validated as tisagenlecleucel, manufactured using next-generation platform <2 days. Here, we report preclinical development preliminary data YTB323 adults with r/r DLBCL (NCT03960840). In mouse models,...
<div>Abstract<p>CAR T-cell product quality and stemness (T<sub>stem</sub>) are major determinants of <i>in vivo</i> expansion, efficacy, clinical response. Prolonged <i>ex culturing is known to deplete T<sub>stem</sub>, affecting outcome. YTB323, a novel autologous CD19-directed CAR therapy expressing the same validated as tisagenlecleucel, manufactured using next-generation platform in <2 days. Here, we report preclinical development...
<p>Supplementary Fig. S1. Preclinical evaluation and characterization of YTB323 CTL*019 for Donor 2 3; Supplementary S2. Differential gene expression cells versus (preclinical); S3. validation YTB323; S4. Dose-dependent expansion (Cmax AUC0-21d) in NSG mice with NALM6; S5. CD4:CD8 ratio comparison leukapheresis cell products tisagenlecleucel; S6. Stemness memory differentiation signatures are retained or enriched final product; S7. tisagenlecleucel S8. Naive/TSCM a naive stem-like...
<p>Supplementary Fig. S1. Preclinical evaluation and characterization of YTB323 CTL*019 for Donor 2 3; Supplementary S2. Differential gene expression cells versus (preclinical); S3. validation YTB323; S4. Dose-dependent expansion (Cmax AUC0-21d) in NSG mice with NALM6; S5. CD4:CD8 ratio comparison leukapheresis cell products tisagenlecleucel; S6. Stemness memory differentiation signatures are retained or enriched final product; S7. tisagenlecleucel S8. Naive/TSCM a naive stem-like...
<p>Supplementary Table S1. Bridging chemotherapies by ATC class and preferred term (safety set); Supplementary S2. Lymphodepleting S3. Cytokine release syndrome following YTB323 infusion; S4. Neurological adverse reactions S5. Summary of cellular kinetic parameters in peripheral blood flow cytometry for at DL1 DL2; S6. qPCR DL2.</p>
<p>Supplementary Table S1. Bridging chemotherapies by ATC class and preferred term (safety set); Supplementary S2. Lymphodepleting S3. Cytokine release syndrome following YTB323 infusion; S4. Neurological adverse reactions S5. Summary of cellular kinetic parameters in peripheral blood flow cytometry for at DL1 DL2; S6. qPCR DL2.</p>
<p>Supplementary Fig. S1. Preclinical evaluation and characterization of YTB323 CTL*019 for Donor 2 3; Supplementary S2. Differential gene expression cells versus (preclinical); S3. validation YTB323; S4. Dose-dependent expansion (Cmax AUC0-21d) in NSG mice with NALM6; S5. CD4:CD8 ratio comparison leukapheresis cell products tisagenlecleucel; S6. Stemness memory differentiation signatures are retained or enriched final product; S7. tisagenlecleucel S8. Naive/TSCM a naive stem-like...
<div>Abstract<p>CAR T-cell product quality and stemness (T<sub>stem</sub>) are major determinants of <i>in vivo</i> expansion, efficacy, clinical response. Prolonged <i>ex culturing is known to deplete T<sub>stem</sub>, affecting outcome. YTB323, a novel autologous CD19-directed CAR therapy expressing the same validated as tisagenlecleucel, manufactured using next-generation platform in <2 days. Here, we report preclinical development...
<p>Supplementary Fig. S1. Preclinical evaluation and characterization of YTB323 CTL*019 for Donor 2 3; Supplementary S2. Differential gene expression cells versus (preclinical); S3. validation YTB323; S4. Dose-dependent expansion (Cmax AUC0-21d) in NSG mice with NALM6; S5. CD4:CD8 ratio comparison leukapheresis cell products tisagenlecleucel; S6. Stemness memory differentiation signatures are retained or enriched final product; S7. tisagenlecleucel S8. Naive/TSCM a naive stem-like...
<p>Supplementary Table S1. Bridging chemotherapies by ATC class and preferred term (safety set); Supplementary S2. Lymphodepleting S3. Cytokine release syndrome following YTB323 infusion; S4. Neurological adverse reactions S5. Summary of cellular kinetic parameters in peripheral blood flow cytometry for at DL1 DL2; S6. qPCR DL2.</p>